Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Castration-Resistant Prostate Cancer (CRPC) Treatment Market Snapshot (2023 to 2033)

The global castration-resistant prostate cancer (CRPC) treatment market is expected to garner a market value of US$ 11.3 Billion in 2023 and is expected to accumulate a market value of US$ 28 Billion by registering a CAGR of 9.5% in the forecast period 2023 to 2033. Growth of the castration-resistant prostate cancer (CRPC) treatment market can be attributed to increasing prevalence of the ailment and use of combination therapies to treat the ailment. The market for castration-resistant prostate cancer (CRPC) treatment registered a CAGR of 6% in the historical period 2018 to 2022

Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that has become resistant to traditional hormone therapy (also known as androgen deprivation therapy or ADT). In CRPC, the cancer continues to grow despite low levels of testosterone in the body, which is typically the result of surgical or medical castration.

Report Attribute Details
Expected Market Value (2023) US$ 11.3 Billion
Anticipated Forecast Value (2033) US$ 28 Billion
Projected Growth Rate (2023 to 2033) 9.5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Castration-Resistant Prostate Cancer (CRPC) Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Castration-Resistant Prostate Cancer (CRPC) Treatment reflected a value of 6% during the historical period, 2018 to 2022.

Increasing prevalence of prostate cancer, the development of new therapies, and the rising demand for personalized medicine is driving the growth of the castration-resistant prostate cancer (CRPC) treatment market. Moreover, research and development along with technological integration for innovating medication is expected to bolster the demand for treatment of castration-resistant prostate cancer (CRPC) treatment market.

Thus, the market for Castration-Resistant Prostate Cancer (CRPC) Treatment is expected to register a CAGR of 9.5% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

Availability of diagnostic tools shaping landscape for CRPC market

The increasing incidence of prostate cancer, which is one of the most common cancers among men, is driving the demand for effective treatments for CRPC. The development of new treatment options, including targeted therapies, immunotherapies, and radiopharmaceuticals, has expanded the range of options available for the treatment of CRPC.

The aging population is more susceptible to prostate cancer and CRPC, and this demographic trend is increasing the demand for effective treatments for this disease. The availability of diagnostic tools such as imaging technologies, genomic testing, and liquid biopsies has improved the detection and monitoring of CRPC, which is contributing to the demand for effective treatments.

The increasing research and development activities in the field of oncology, including prostate cancer, are leading to the development of new and innovative treatments for CRPC. The government initiatives aimed at increasing awareness of prostate cancer and improving access to healthcare services are contributing to the growth of the CRPC treatment market.

Presence of different treatments creative lucrative opportunities for CRPC market

Second-line hormone therapy: This involves the use of different types of hormone therapy drugs that target different aspects of the androgen receptor pathway.

Chemotherapy: Chemotherapy drugs such as docetaxel and cabazitaxel may be used to treat CRPC.

Immunotherapy: Immune checkpoint inhibitors such as pembrolizumab and nivolumab have been approved for the treatment of certain types of CRPC.

Radiopharmaceutical therapy: Radiopharmaceuticals such as radium-223 and lutetium-177 PSMA have been approved for the treatment of CRPC that has spread to the bones.

Targeted therapy: Targeted drugs such as enzalutamide, abiraterone, and apalutamide may be used to treat CRPC by blocking specific pathways that fuel the growth of cancer cells.

Clinical trials: Participation in clinical trials of new treatments is also an option for some patients with CRPC.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

Limited efficiency of treatments along with expensive nature of treatment affecting market growth

Many of the available treatment options for CRPC are expensive, and this can make them inaccessible to patients who cannot afford them or are not covered by health insurance. The side effects of many CRPC treatments, such as chemotherapy and immunotherapy, can be severe and impact a patient's quality of life. This can make it challenging for patients to tolerate the treatments and continue with their treatment plans.

While there are several treatment options available for CRPC, not all of them are effective for every patient. Some patients may not respond to certain treatments, and this can limit the efficacy of the available options. Some patients may develop resistance to the available treatments, which can make it challenging to manage their disease and prolong their survival.

Despite the advances in research and development, the underlying mechanisms of CRPC are not fully understood, and this can make it challenging to develop new and more effective treatments. Developing new treatments for CRPC can be challenging due to regulatory requirements, including the need for extensive clinical trials to demonstrate safety and efficacy. All these factors are derailing the growth of CRPC market.

Region-Wise Insights

Advanced Healthcare Infrastructure Boosting Market Growth of CRPC in North America?

Newer targeted therapies creating lucrative opportunities for CPRC treatment

The North American market for Castration-Resistant Prostate Cancer (CRPC) treatment is one of the largest markets in the world, due to the high prevalence of prostate cancer in the region and the availability of advanced healthcare infrastructure.

In terms of treatment options, chemotherapy and hormone therapy have been the mainstays of CRPC treatment in North America for many years, but newer targeted therapies such as abiraterone, enzalutamide, apalutamide, and radium-223 have also been approved for use. Immunotherapy, such as the use of immune checkpoint inhibitors, is also being investigated for CRPC treatment. Thus, North America is expected to possess 46% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.

Introduction of Novel Treatments Supporting Growth of CRPC Treatment Market in Europe?

Increasing awareness of diagnosis propelling demand for CRPC treatment in Europe

The Europe CRPC treatment market is being driven by the increasing prevalence of the disease in the region, as well as the growing awareness and diagnosis of the disease. In addition, the market is being driven by the introduction of novel treatments that offer better efficacy and fewer side effects than traditional therapies.

One of the most promising developments in CRPC treatment is the use of targeted therapies. These drugs are designed to specifically target the cancer cells and limit their growth and spread, while minimizing damage to healthy cells. Targeted therapies such as enzalutamide and abiraterone have shown significant benefits in treating CRPC, leading to their approval by regulatory agencies in Europe. Thus, Europe is expected to possess 40% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Ease and Accessibility of Consuming Oral Medications Making Them Popular for CRPC Treatment?

Ease to administer oral medication increasing dependency to treat CRPC treatment

The oral route offers patients the convenience of taking medication in the comfort of their own homes. This is particularly beneficial for CRPC patients, who may need to take medication for extended periods of time. Oral medications can be taken without the need for hospital visits or invasive procedures, making treatment more accessible and less disruptive to a patient's daily life.

In addition, the oral route of administration can help to improve patient adherence to treatment. Patients are more likely to take their medication as prescribed when it is delivered in a convenient, easy-to-administer format. This is particularly important in the treatment of CRPC, where adherence to therapy is crucial for achieving positive treatment outcomes. Thus, by drug delivery method, oral route is expected to possess 55% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.

Market Competition

Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation

  • In 2018, Sanofi and Regeneron Pharmaceuticals announced the results of a phase 3 clinical trial investigating the use of their immunotherapy drug, cemiplimab, in combination with Jevtana for the treatment of metastatic CRPC. The trial showed promising results, with the combination therapy significantly improving overall survival and progression-free survival compared to Jevtana alone.
  • In 2019, Pfizer announced the results of a phase 3 clinical trial investigating the use of Xtandi in combination with abiraterone acetate, another androgen receptor inhibitor, for the treatment of metastatic CRPC.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 11.3 Billion
Market Value in 2033 US$ 28 Billion
Growth Rate CAGR of 9.5% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Therapy Type
  • Drug Class
  • Drug Delivery Method
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Rest of Latin America
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Rest of South Asia
  • China
  • Japan
  • South Korea
  • Austria
  • New Zealand
  • GCC countries
  • South Africa
  • Israel
  • Rest of MEA
Key Companies Profiled
  • Sanofi S.A.
  • Johnson and Johnson
  • Pfizer, Inc.
  • Bayer AG
  • Abbott Laboratories
  • GlaxoSmithKline PLC
  • Northwest Biotherapeutics, Inc.
  • Active Biotech AB
  • Astellas Pharma, Inc
  • Dendreon Corporation
Customization Available Upon Request

Key Segments Profiled in the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry Survey

Therapy Type:

  • Hormonal therapy
  • Chemotherapy
  • Immunotherapy
  • Radiotherapy

Drug Class:

  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Microtubule Inhibitor

Drug Delivery Method:

  • Oral Route
  • Injectable Route

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

Frequently Asked Questions

Which region holds high lucrativeness in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

The Asia Pacific region is projected to emerge as a lucrative market for Castration-Resistant Prostate Cancer (CRPC) Treatment.

What is the growth potential of the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

The growth potential of the Castration-Resistant Prostate Cancer (CRPC) Treatment market is 8% through 2033.

What limits the growth potential of the Market?

The high cost of treatment is likely to limit market growth.

What is North America's expected share in 2023?

North America is likely to generate 46% revenue in 2023.

What is the Projected Size of the Market by 2033?

The global market size to reach US$ 28 billion by 2033.

Table of Content

1. Executive Summary | Castration-Resistant Prostate Cancer (CRPC) Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033

        5.3.1. Hormonal therapy

        5.3.2. Chemotherapy

        5.3.3. Immunotherapy

        5.3.4. Radiotherapy

    5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        6.3.1. Antineoplastic

        6.3.2. Non-steroidal Antiandrogen

        6.3.3. Corticosteroids

        6.3.4. Microtubule Inhibitor

    6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Delivery Method 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Drug Delivery Method , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Delivery Method , 2023 to 2033

        7.3.1. Oral Route

        7.3.2. Injectable Route

    7.4. Y-o-Y Growth Trend Analysis By Drug Delivery Method , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Drug Delivery Method , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. South Asia

        9.3.5. East Asia

        9.3.6. Oceania

        9.3.7. MEA

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. USA

            10.2.1.2. Canada

        10.2.2. By Therapy Type

        10.2.3. By Drug Class

        10.2.4. By Drug Delivery Method

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapy Type

        10.3.3. By Drug Class

        10.3.4. By Drug Delivery Method

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Therapy Type

        11.2.3. By Drug Class

        11.2.4. By Drug Delivery Method

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapy Type

        11.3.3. By Drug Class

        11.3.4. By Drug Delivery Method 

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. United Kingdom

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Therapy Type

        12.2.3. By Drug Class

        12.2.4. By Drug Delivery Method

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapy Type

        12.3.3. By Drug Class

        12.3.4. By Drug Delivery Method

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Rest of South Asia

        13.2.2. By Therapy Type

        13.2.3. By Drug Class

        13.2.4. By Drug Delivery Method

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Therapy Type

        13.3.3. By Drug Class

        13.3.4. By Drug Delivery Method

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Therapy Type

        14.2.3. By Drug Class

        14.2.4. By Drug Delivery Method

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Therapy Type

        14.3.3. By Drug Class

        14.3.4. By Drug Delivery Method

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. Australia

            15.2.1.2. New Zealand

        15.2.2. By Therapy Type

        15.2.3. By Drug Class

        15.2.4. By Drug Delivery Method

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Therapy Type

        15.3.3. By Drug Class

        15.3.4. By Drug Delivery Method

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Therapy Type

        16.2.3. By Drug Class

        16.2.4. By Drug Delivery Method

        16.2.5. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Therapy Type

        16.3.3. By Drug Class

        16.3.4. By Drug Delivery Method

        16.3.5. By Distribution Channel

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Therapy Type

            17.1.2.2. By Drug Class

            17.1.2.3. By Drug Delivery Method

            17.1.2.4. By Distribution Channel

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Therapy Type

            17.2.2.2. By Drug Class

            17.2.2.3. By Drug Delivery Method

            17.2.2.4. By Distribution Channel

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Therapy Type

            17.3.2.2. By Drug Class

            17.3.2.3. By Drug Delivery Method

            17.3.2.4. By Distribution Channel

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Therapy Type

            17.4.2.2. By Drug Class

            17.4.2.3. By Drug Delivery Method

            17.4.2.4. By Distribution Channel

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Therapy Type

            17.5.2.2. By Drug Class

            17.5.2.3. By Drug Delivery Method

            17.5.2.4. By Distribution Channel

    17.6. United Kingdom

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Therapy Type

            17.6.2.2. By Drug Class

            17.6.2.3. By Drug Delivery Method

            17.6.2.4. By Distribution Channel

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Therapy Type

            17.7.2.2. By Drug Class

            17.7.2.3. By Drug Delivery Method

            17.7.2.4. By Distribution Channel

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Therapy Type

            17.8.2.2. By Drug Class

            17.8.2.3. By Drug Delivery Method

            17.8.2.4. By Distribution Channel

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Therapy Type

            17.9.2.2. By Drug Class

            17.9.2.3. By Drug Delivery Method

            17.9.2.4. By Distribution Channel

    17.10. India

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Therapy Type

            17.10.2.2. By Drug Class

            17.10.2.3. By Drug Delivery Method

            17.10.2.4. By Distribution Channel

    17.11. Malaysia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Therapy Type

            17.11.2.2. By Drug Class

            17.11.2.3. By Drug Delivery Method

            17.11.2.4. By Distribution Channel

    17.12. Singapore

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Therapy Type

            17.12.2.2. By Drug Class

            17.12.2.3. By Drug Delivery Method

            17.12.2.4. By Distribution Channel

    17.13. Thailand

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Therapy Type

            17.13.2.2. By Drug Class

            17.13.2.3. By Drug Delivery Method

            17.13.2.4. By Distribution Channel

    17.14. China

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Therapy Type

            17.14.2.2. By Drug Class

            17.14.2.3. By Drug Delivery Method

            17.14.2.4. By Distribution Channel

    17.15. Japan

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Therapy Type

            17.15.2.2. By Drug Class

            17.15.2.3. By Drug Delivery Method

            17.15.2.4. By Distribution Channel

    17.16. South Korea

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Therapy Type

            17.16.2.2. By Drug Class

            17.16.2.3. By Drug Delivery Method

            17.16.2.4. By Distribution Channel

    17.17. Australia

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Therapy Type

            17.17.2.2. By Drug Class

            17.17.2.3. By Drug Delivery Method

            17.17.2.4. By Distribution Channel

    17.18. New Zealand

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Therapy Type

            17.18.2.2. By Drug Class

            17.18.2.3. By Drug Delivery Method

            17.18.2.4. By Distribution Channel

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Therapy Type

            17.19.2.2. By Drug Class

            17.19.2.3. By Drug Delivery Method

            17.19.2.4. By Distribution Channel

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Therapy Type

            17.20.2.2. By Drug Class

            17.20.2.3. By Drug Delivery Method

            17.20.2.4. By Distribution Channel

    17.21. Israel

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Therapy Type

            17.21.2.2. By Drug Class

            17.21.2.3. By Drug Delivery Method

            17.21.2.4. By Distribution Channel

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Therapy Type

        18.3.3. By Drug Class

        18.3.4. By Drug Delivery Method

        18.3.5. By Distribution Channel

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Sanofi S.A.

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Johnson and Johnson

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Pfizer, Inc.

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. Bayer AG

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Abbott Laboratories

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. GlaxoSmithKline PLC

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Northwest Biotherapeutics, Inc.

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Active Biotech AB

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Astellas Pharma, Inc.

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Dendreon Corporation

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Prosthetic Heart Valve Market

Published : October 2023

Healthcare

Psychotropic Drugs Market

Published : October 2023

Healthcare

Prostate Health Market

Published : January 2023

Healthcare

Prostate Cancer Market

Published : December 2022

Explore Healthcare Insights

View Reports

Castration-Resistant Prostate Cancer (CRPC) Treatment Market